Focus

Opthea is committed to improving vision in patients suffering with retinal eye diseases.

We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies.

OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.

LEARN MORE

Disease

Wet AMD is the leading cause of blindness in the developed world in people aged over 50 years. It is caused by the abnormal growth and leakage of blood vessels at the back of the eye, which causes degeneration of the retina and vision loss.

Learn More

Technology

Opthea’s technology is centred on two members of the Vascular Endothelial Growth Factor (VEGF) family of proteins, VEGF-C and VEGF-D, and their activation of VEGF receptors.These proteins promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3, and lymphatic vessel development (lymphangiogenesis), by activation of VEGFR-3.

Learn More

Opportunity

Both wet AMD and DME are associated with vascular dysfunction and fluid accumulation at the back of the eye in a region of the central retina or ‘macula’ that is needed for sharp, central vision. Vessel growth and vascular leakage are primarily driven by members of the vascular endothelial growth factor (VEGF) family, which comprises 5 members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF).

Learn More

OPT-302

OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Learn More

Clinical Trials

Opthea has completed a Phase 2b clinical trial investigating OPT-302 in wet AMD patients, and has completed a Phase 1b/2a clinical trial in patients with DME. Opthea is planning to initiate two pivotal Phase 3 clinical trials for the treatment of wet AMD in the first half of 2021.

Learn more

WITH CLINICAL TRIALS PROGRESSING
AND DATA LOOKING PROMISING,
WE BELIEVE OPT-302 WILL IMPROVE
OUTCOMES FOR PATIENTS WITH
THESE DEBILITATING DISEASES.

Opthea Researcher

Announcements

Opthea Presents at the Oppenheimer 31st Annual Healthcare Conference

17 March 2021

Dr Megan Baldwin, CEO of Opthea, presented a corporate update at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021

Read the presentation slides

Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD

15 March 2021

Opthea announced that the first patient has been treated in the Phase 3 pivotal clinical program of the Company’s first-in-class VEGF-C/D ‘trap’ inhibitor, OPT-302, in participants with treatment-naive wet AMD

Read More

MST Access Initiates Opthea Coverage

9th December 2020

MST Access has released its initiation of coverage report – Opthea Limited: In its ‘Lines’ of Sight

Read the report

Opthea Announces Pricing of Initial Public Offering in the United States

19th October 2020

Opthea has announced it has priced its IPO in the United States and that the company’s ADSs have commenced trading on the NASDAQ.

Read More

ALL ANNOUNCEMENTS